The DOI matches its Crossref record; 193 of the 195 references it cites were found in a registry or an index.
BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment
Abstract
Excess deaths from cardiovascular disease are a major contributor to the significant reduction in life expectancy experienced by people with schizophrenia. Important risk factors in this are smoking, alcohol misuse, excessive weight gain and diabetes. Weight gain also reinforces service users’ negative views of themselves and is a factor in poor adherence with treatment. Monitoring of relevant physical health risk factors is frequently inadequate, as is provision of interventions to modify these. These guidelines review issues surrounding monitoring of physical health risk factors and make recommendations about an appropriate approach. Overweight and obesity, partly driven by antipsychotic drug treatment, are important factors contributing to the development of diabetes and cardiovascular disease in people with schizophrenia. There have been clinical trials of many interventions for people experiencing weight gain when taking antipsychotic medications but there is a lack of clear consensus regarding which may be appropriate in usual clinical practice. These guidelines review these trials and make recommendations regarding appropriate interventions. Interventions for smoking and alcohol misuse are reviewed, but more briefly as these are similar to those recommended for the general population. The management of impaired fasting glycaemia and impaired glucose tolerance (‘pre-diabetes’), diabetes and other cardiovascular risks, such as dyslipidaemia, are also reviewed with respect to other currently available guidelines. These guidelines were compiled following a consensus meeting of experts involved in various aspects of these problems. They reviewed key areas of evidence and their clinical implications. Wider issues relating to primary care/secondary care interfaces are discussed but cannot be resolved within guidelines such as these.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Maudsley [34] and British Association of Psychopharmacology [33] treatment algorithms explicitly identify off-label metformin as firstline options when treating AIWG and OSP in nondiabetics, with the latter citing a lack of human data to support recommending licensed options.”
From A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. (2022) · cites this paper as [33]
In the citing paper
“On the other hand, the magnitude is similar to the magnitude of weight lost from lifestyle interventions (79, 80) and by adding topiramate or metformin to current antipsychotic medication, all being recommended in clinical guidelines (81).”
From Reversibility of Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis (2021) · cites this paper as [81]
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. (1989) · Technometrics · doi:10.1080/00401706.1989.10488618 · Cited by 99,167
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382 · cited 1×
“It is clear from the initial meta-analysis of RCT data by Allison et al. (1999) to the recent indirect, multiple treatments, meta-analysis from Leucht et al.”
BackgroundTiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354 · cited 1×
“The life expectancy of people with schizophrenia is reduced by over 20 years (Tiihonen et al., 2009).”
Background
Research works printed but not linked: 27
- Bennett ME, 2013, Curr Drug Abuse Rev, 13, 180
- Das C, 2012, Ann Clin Psychiatry, 24, 225
- Hoghton M, 2010, A Step by Step Guide for GP Practices: Annual Health Checks for People with a Learning Disability
- Horst WD, 2005, Neuropsychiatric Dis Treat, 1, 349
- 10.1176/ps.62.8.pss6208_0882 · doi:10.1176/ps.62.8.pss6208_0882
- 10.1192/bjp.183.6.534 · DOI · Paper page
- McQuade RD, 2004, J Clin Psychiatry, 65, 47
- NICE, 2002, Schizophrenia: Core interventions in the treatment and management of schizophrenia in primary and secondary care
- NICE, 2009, Psychosis and schizophrenia: management
- NICE, 2011, Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence
- NICE, 2012, Type 2 diabetes: prevention in people at high risk
- NICE, 2013, Psychosis and schizophrenia in children and young people: recognition and management
- NICE, 2014, Psychosis and schizophrenia in adults: prevention and management
- NICE, 2014, Cardiovascular disease: risk assessment and reduction, including lipid modification
- NICE, 2014, Obesity: identification, assessment and management
- NICE, 2015, Obesity: identification, assessment and management
- NICE, 2015, Psychosis and schizophrenia in adults
- NICE, 2015, Psychosis and schizophrenia in children and young people
- Public Health England, 2016, NHS Health Check: best practice guidance
- Puska P, 1998, Bull WHO, 76, 419
- Royal College of Psychiatrists, 2010, No health without public mental health: the case for action
- Royal College of Psychiatrists, 2012, Report of the National audit of Schizophrenia (NAS) 2012
- Royal College of Psychiatrists, 2014, Report of the second round of the National audit of Schizophrenia (NAS) 2014
- Schizophrenia Commission, 2012, The abandoned illness: a report from the Schizophrenia Commission
- Shiers DE, 2014, Positive Cardiometabolic Health Resource: an intervention framework for patients with psychosis and schizophrenia. 2014 update (with acknowledgement to the late Helen Lester for her contribution to the original 2012 version)
- Smith J, 2014, Early Interv Psychiatry, 8, 30
- Taylor D, 2012, The Maudsley Prescribing Guidelines in Psychiatry, 11th edn
Cited by
Firth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., Allan, S., Caneo, C., Carney, R., Carvalho, A. F., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30132-4 · Cited by 1,531
“Weight gain is the most distressing side-effect reported by callers to mental health helplines, 188 and is associated with poorer quality of life 239–241 and barriers to social engagement.”
Self-citationPillinger, T., McCutcheon, R. A., Vano, L., Mizuno, Y., Arumuham, A., Hindley, G., Beck, K., Natesan, S., Efthimiou, O., Cipriani, A., et al. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30416-x · Cited by 1,090
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Self-citationAntipsychotic-associated weight gain: management strategies and impact on treatment adherence
Dayabandara, M., Hanwella, R., Ratnatunga, S., Seneviratne, S., Suraweera, C., & de Silva, V. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s113099 · Cited by 367
“These interventions are often referred to as “behavioral lifestyle programs”.(53) Both individual interventions and group interventions have been studied.”
BackgroundA Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
Koblan, K. S., Kent, J., Hopkins, S. C., Krystal, J. H., Cheng, H., Goldman, R., & Loebel, A. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911772 · Cited by 297
Metadata
- Authors
- Cooper, S. J., Reynolds, G. P., order):, W. E. C.-A. (. A., Barnes, T., England, E., Haddad, P., Heald, A., Holt, R., Lingford-Hughes, A., Osborn, D., McGowan, O., Patel, M., Paton, C., Reid, P., Shiers, D., & Smith, J.
- Affiliations
- Queen's University Belfast (GB)
- Centre for Mental Health (GB)
- University of Manchester (GB)
- Honorary Clinical Professor of Psychiatry, University of Manchester, Manchester, UK
- Central and North West London NHS Foundation Trust (GB)
- Hairmyres Hospital (GB)
- King's College London (GB)
- Oxleas NHS Foundation Trust (GB)
- Rethink Mental Illness (GB)
- Royal College of Psychiatrists (GB)
- University of Worcester (GB)
- ORCID
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2016-05-04
- Volume
- 30
- Issue
- 8
- Pages
- 717-748
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2347099014
- Cited by
- 292
- References
- 195
- Citations by year
- 2026: 29 · 2025: 27 · 2024: 38 · 2023: 32 · 2022: 30 · 2021: 50 · 2020: 25 · 2019: 21 · 2018: 22 · 2017: 18
- FWCI
- 18.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Worcester Research and Publications (University of Worcester) (acceptedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- SHURA (Sheffield Hallam University Research Archive) (Sheffield Hallam University) (submittedVersion)
- Funders
- National Institute for Health and Care Research (RP-PG-0609-10156, NIHR/CS/009/010)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
- Keywords
- antipsychotic-induced weight gain, schizophrenia, cardiovascular risk, diabetes mellitus, impaired fasting glucose, impaired glucose tolerance, dyslipidemia, smoking, alcohol abuse, physical health monitoring, obesity, antipsychotic adverse effects, medication adherence
- MeSH terms
- Cardiovascular Diseases, Humans, Metabolic Diseases, Obesity, Psychotic Disorders, Risk Factors, Schizophrenia, Antipsychotic Agents, Weight Gain, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. https://app.cochat.ai/papers/10.1177/0269881116645254
- The paper
- Cooper, S. J., Reynolds, G. P., order):, W. E. C.-A. (. A., Barnes, T., England, E., Haddad, P., Heald, A., Holt, R., Lingford-Hughes, A., Osborn, D., McGowan, O., Patel, M., Paton, C., Reid, P., Shiers, D., & Smith, J. (2016). BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. Journal of Psychopharmacology. https://doi.org/10.1177/0269881116645254
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.